Many people are confused about what the International Consensus Classification (ICC) of hematolymphoid tumors is. Today, we will briefly introduce it. To introduce the origin of the ICC, it is inevitable to discuss the origin of the 5th edition of the World Health Organization (WHO) classification, and it is also necessary to review how past … Read more
Author Introduction Li Yuejun, Director of the Clinical Trial Center and Research Director of the Oncology Medical Center at Hunan Provincial Traditional Chinese Medicine Hospital. Medical Doctor, Chief Physician, Master’s Supervisor, and High-level Health Talent in Hunan Province. Engaged in clinical oncology, research, and teaching for over 10 years. Specializes in multidisciplinary comprehensive treatment of … Read more
August 7, 2025 Baiaoshaitu WO2025161939 FOLR1/MUC1 ADC On August 7, Baiaoshaitu disclosed an ADC patent targeting FOLR1 and FOLR1/MUC1. According to the data disclosed in the patent examples, the preferred structure for the FOLR1-targeted ADC is 1A3-CPT2, while the preferred structure for the FOLR1/MUC1 dual-targeted ADC is 10G1-1A3-CPT2; where 1A3 targets FOLR1 and 10G1 targets … Read more
From May 30 to June 3, 2025, the largest global oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, was held in Chicago, USA. Researchers including Philippe Armand presented data from the waveLINE-003 Phase II study, exploring the recommended treatment dose, safety, and efficacy of the novel antibody-drug conjugate (ADC) Zilovertamab vedotin (ZV) … Read more
Company Overview MediLink Therapeutics was founded in 2020, headquartered in Suzhou (with a research branch in Boston, USA), and has established research institutions in Shanghai and Singapore. The company’s founder, Dr. Xue Tongtong, previously served as the general manager of Kelun-Biotech and has over 10 years of experience in the research and management of antibodies, … Read more
Click the blue text Follow us This Issue Focus Point B7-H4 is a member of the B7 immune checkpoint ligand family, which has been shown to bind to an unknown receptor on T cells, inhibiting T cell proliferation and cytokine production, thereby negatively regulating T cell function. The expression level of B7-H4 is elevated in … Read more
The abstract from AACR hides a new modality. Following yesterday’s TCE conjugated ADC, there is also the Triple-payload ADC project submitted by Araris. Currently, only the abstract has been released, indicating that this is an ADC molecule targeting Nectin-4, designed with MMAE and dual Topo1i as a triple payload. Below is the full abstract:Araris’s site-specific … Read more
GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more
Medical researchers are not only continuously developing new anti-tumor drugs but are also trying to find new uses for old drugs, hoping to alleviate the suffering caused by cancer and extend survival. High-dose vitamin C treatment for cancer is one of these methods, which is still under research. Many people may wonder how vitamin C, … Read more
Compiled by: Oncology News Source: Oncology News PET/CT has currently been recommended for imaging assessment at the initial diagnosis of multiple myeloma (MM) patients, as well as for evaluating the efficacy after treatment. In recent years, with the application of new drugs and autologous stem cell transplantation (ASCT), it has become possible for MM patients … Read more